The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Deepestblue
You're talking rubbish, the fact that there is a secondary market means that those that buy at IPO can sell their stake whenever they want to. How many shares would you buy at IPO if you could never sell them later? It's exactly the same as the car market, buying a brand used helps the manufacturer, because people will pay a higher price for the new model, if it has a strong second hand value
Seems odd that someone who has been warning on of doom for so long is still a shareholder, if I had your attitude i would have sold up ages ago. Why do you continue to hold,? Logical conclusion would be you don't believe what you post
If you can't interpret "Parsortix is not a screening device" a quote AN has repeated multiple times, it's you that has the problem. There is not one study published that set out to prove Parsortix as a first line detection system
JTT
AN has said on many occasions that the intended use for Parsortix is to benefit treatment not for screening. It is no secret. You need to be more thorough with your research before you insist on people being brought to justice
Researcher. A deal could come in 3 weeks time and the FCA could do FA about it if they couldn't prove any wrong doing. A deal isn't a deal until it's signed and discussions with other companies are public knowledge, no secrets and are part of day to day business
Mr Ripley. I hear and believe what you are saying, but It's not impossible that you have been given duff information by a junior, after all it's just before Christmas close. Perhaps the cleaners have been asked to man the desks. I find it hard to believe IG would accept instructions from Avacta, or that it would be legal, even in common law, let alone financial regulation
Our requirement included the completion of the Rochester Ovarian study that was completed recently, although I don't believe we will be restricted to Ovarian services, just that study used as a sampler if you like
Research use of the labs although welcome is chicken feed compared to something like a possible deal with Solaris for example, for clinical services. Research studies and trials are typically under 200 patients, Solaris treat 750k patients per year. For that reason when I concider contracts, I'm only really thinking of clinical. I don't think the odd research study is going to shift the SP much
My understanding was that until the labs are accredited that they can only be used for study and research use, and accreditation is required to provide direct clinical services for patients. Are you saying that is incorrect
From FDA.gov CLIA page
Diagnostic testing helps health care providers screen for or monitor specific diseases or conditions. It also helps assess patient health to make clinical decisions for patient care. The Clinical Laboratory Improvement Amendments (CLIA) regulate laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing. Laboratories can obtain multiple types of CLIA certificates, based on the kinds of diagnostic tests they conduct.
https://www.fda.gov/medical-devices/ivd-regulatory-assistance/clinical-laboratory-improvement-amendments-clia
Researcher, a bit hypocritical of you complaining that AN sold some of his shares(not all), when you sold the majority of yours immediately after FDA.
Contract deals are a 2 way negotiation, you can't just make them appear. And no one is going to sign a lab deal until CLIA is complete(a decision in the hands of a third party, not Angle). If you read the statement of corporate governance you will see that the BOD of non executive directors are not encouraged to have anything other than a minor share holding for reasons of holding an Independent status. How do you know that negotiations are not underway, but AN is not rolling over to the first crap offer. If I felt like yourself having no faith in the company, I'd sell up and move on.
AN did not say he only wanted rich holders, he said he was not interested in short term traders.